The thyroid cancer therapeutics pipeline is expected to witness considerable growth due to increase in the demand for the targeted drug formulation for the treatment of cancer. Though less number of drugs are available for thyroid cancer treatment, an increasing awareness regarding cancer treatment and high demand for safe and effective medications are driving the therapeutics pipeline.
According to the National Cancer Institute, a part of the U.S. National Institutes of Health, thyroid cancer is a rare type of cancer that affects the thyroid gland, a small gland at the base of the neck that produces hormones. It most commonly occurs in people aged 30-year-old. Women are two to three times more likely to develop this thyroid cancer, as compared to men. Thyroid cancer is usually treatable, and in many cases, can be cured completely, although it can sometimes come back after treatment. There are four main types of thyroid cancer; papillary thyroid cancer, follicular thyroid cancer (hurthle cell thyroid cancer), medullary thyroid cancer and anaplastic thyroid cancer.
The pipeline drugs for the treatment of thyroid cancer contains Ofranergene obadenovec, a Phase II drug candidate of Vascular Biogenics Ltd. It is an intravenously administered dual-action, anti-angiogenic and vascular disrupting agent. It is a targeted anti-cancer gene-therapy agent, which consists of a non-replicating adenovirus vector with a pre-proendothelin-1 promoter that encodes a Fas-Chimera transgene apoptotic receptor in tumor blood vessel endothelial cells, leading to their apoptosis. This mechanism retains activity, regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. Vascular Biogenics is using vascular targeting system technology platform, which controls gene expression to either promote or prevent angiogenesis to target various diseases. The drug induces specific anti-tumor immune response, followed by entry of CD8 T-cells and apoptosis of tumor cells. Eisai Inc. is currently conducting a trial of lenvatinib in radio-iodine for refractory differentiated thyroid cancer in China, which is currently in Phase III clinical development.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/thyroid-cancer-therapeutics-pipeline-analysis/toc-sample
Many pharmaceutical companies are focusing on the research and development of thyroid cancer therapeutics pipeline drug candidates, collaborating with one another. In February 2015, Biologics, Inc., an integrated oncology services company, reported that it was selected by Eisai Co. Ltd. as a specialty pharmacy provider within Eisai’s limited distribution network for Lenvima (lenvatinib).
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)